Hashtag
Men's Weekly

How to Choose the Best Asbestos Removalist Melbourne for Your Construction Project

When planning a construction or renovation project in Melbourne, ensuring the safety of your site is paramount. One of the hidde...

How Does a Dual Battery System Actually Work

A dual battery system is essential for those who love off-grid adventures or need reliable power for work vehicles. It plays a cru...

What Makes a Power Pack Essential for Off-Grid Trips

Embarking on an off-grid adventure invites you to reconnect with nature, far from the convenience of the electric grid. Yet, stayi...

Are Home Solar Panels Worth the Investment Today?

Solar panels offer the promise of significant energy savings and a smaller carbon footprint. Homeowners are increasingly aware of ...

A Permanent Fix: Why More Patients Are Choosing Dental Implants

Among the myriad of advancements in the field of dentistry, none have impacted as radically as dental implants. A last option no...

Smile Confidently: Sydney's Best Cosmetic Dentists for Invisalign Treatment

A warm, welcoming smile can change how you see yourself and how others see you. But to so many, crooked or uneven teeth will obs...



The Company is currently the first enterprise in China and the second enterprise in the world to apply for the clinical trial of a long-acting triple agonist of GLP-1 (glucagon-like peptide-1)/GIP (glucose-dependent insulinotropic polypeptide)/GCG (glucagon) prepared by chemical synthesis peptide.

UBT251 is a long-acting polypeptide drug that stimulates triple-target receptors for GLP-1/GIP /GCG simultaneously. By acting on GLP-1 receptors, GIP receptors and GCG receptors, UBT251 promotes insulin secretion, regulates appetite and energy metabolism, reduces blood glucose and weight, and improves liver steatosis. Preclinical studies in various animal models have proven that UBT251 significantly reduces blood glucose and weight, improves liver steatosis and fibrosis, and that it outperforms the marketed single-target GLP-1 receptor drug Semaglutide and the dual-target GLP-1/GIP drug Tirzepatide in the in-vivo treatment of model animals.

The product is expected to be beneficial for the treatment of patients with various metabolic disorders such as type 2 diabetes, overweight/obesity and NASH, when administered once a week by subcutaneous injection. At present, the fastest progress in the R&D of the same target drugs, both domestic and abroad, has just announced the initiation of phase III clinical trials.

Mr. Tsoi Hoi Shan, Chairman of the Group said that, "TUL has focused on the field of diabetes for several years and is one of the few pharmaceutical companies in China that owns both second and third generation insulin products. As the Group's biopharmaceutical R&D headquarters, The United Bio-Technology specialises in the research and development of drug products for energy metabolism, inflammation and autoimmune diseases. The primary mission of United Bio-Technology is the research and development of high-end biological drugs for the treatment of major chronic diseases. The United Bio-Technology's self-developed class 1 innovative new drug UBT251 Injection fully demonstrates the Group's innovation and R&D capability in biopharmaceutical industry. In the future, we will continue to actively promote the progress of new drug projects, and focus on enhancing its competitiveness and creativity in the biopharmaceutical industry, with a view of creating more benefits for the Company and its shareholders."

Hashtag: #TUL

The issuer is solely responsible for the content of this announcement.

About The United Laboratories International Holdings Limited (TUL)

TUL is one of the leading comprehensive pharmaceutical companies in China, principally engaged in the R&D, manufacturing and selling of finished products, bulk medicines and intermediate products. Its products include drugs for human use and animal healthcare. The Group has six production bases, and its sales teams for intermediate products, bulk medicines and finished products formed a broad sales network covering China and the rest of the world. Currently, TUL is one of the few pharmaceutical companies in China that owns both second and third generation insulin products. The Group is presently a constituent of the Hang Seng Composite Index Series and maintains MSCI ESG rating at A, which is an industry-leading rating.

IN THE NEWS

Most Common Health Hazards for Office Workers

Working in an office has its ups and downs just like any other way of working. It isn’t the best or.

Coface Asia Payment Survey 2025 Companies expect payment behaviours to worsen amid economic uncertai…

HONG KONG SAR / SHANGHAI & BEIJING, CHINA / TAIPEI, TAIWAN / SYDNEY, AUSTRALIA / TOKYO, JAPAN - Medi.

ZJLD Awarded the 2024 Hong Kong Corporate Governance and ESG Excellence Award by the Chamber of Hong…

HONG KONG SAR - Media OutReach Newswire - 20 December 2024 - The first baijiu company listed on the Hong.

Nomination period for the Broermann Medical Innovation Award started

Prize money of one million euros higher than the prize money for the Nobel Prize for Medicine .

Understanding Different Loan Products: Which One is For You

The choice of a loan product is extremely important if you want to achieve your financial goals. There .

Finexcellent Ramadan: Trade, Learn, and Give Back

JAKARTA, INDONESIA - Media OutReach Newswire - 14 March 2025 - Finex, an acclaimed Indonesian broker, h.

Health & Wellness

A Permanent Fix: Why More Patients Are Choosing Dental Implants

Hashtag.net.au - avatar Hashtag.net.au

Among the myriad of advancements in the field of dentistry, none have impacted as radically as dental implants. A last option not long ago, today, implants are the go-to solution for millions of ind...

Smile Confidently: Sydney's Best Cosmetic Dentists for Invisalign Treatment

Hashtag.net.au - avatar Hashtag.net.au

A warm, welcoming smile can change how you see yourself and how others see you. But to so many, crooked or uneven teeth will obstruct smiling openly. Modern cosmetic dentistry has answers, though, t...

Will Anyone Notice My Clear Aligners? Here’s the Honest Truth

Hashtag.net.au - avatar Hashtag.net.au

Image by freepikClear aligners have become hugely popular in Australia, promising discreet orthodontic treatment without the obvious look of metal braces. Yet, despite their growing popularity, a co...